Lupin Gets USFDA Nod To Market Prucalopride Tablets

Lupin Ltd. on Wednesday said it has received approval from the US Food and Drug Administration to market Prucalopride Tablets in 1 mg and 2 mg strengths. The product is a generic version of Motegrity tablets, originally developed by Takeda Pharmaceuticals USA Inc.

The tablets will be manufactured at Lupin’s facility in Goa, the company said in a press release. The drug is indicated for the treatment of chronic idiopathic constipation in adults.

According to IQVIA data quoted by Lupin, Prucalopride Tablets had estimated annual sales of $184 million in the US for the 12 months ended April.